Opinion|Videos|February 18, 2026
Data for Lenvatinib Plus Pembrolizumab and TACE in Unresectable, Nonmetastatic HCC
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss data for lenvatinib, pembrolizumab, and TACE from LEAP-012 in HCC.
Advertisement
Episodes in this series
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss findings from LEAP-012 evaluating lenvatinib plus pembrolizumab combined with TACE in this setting. Chan outlines the biologic rationale for integrating systemic immunotherapy and antiangiogenic therapy with locoregional treatment to enhance tumor necrosis and immune activation. Cantis reviews key efficacy and safety outcomes and considers how this triplet strategy may compare with TACE alone in terms of response, progression control, and tolerability.
Advertisement
Related to this article
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.
OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.
Micvotabart pelidotin produced a 36% confirmed ORR and a 6.2-month median PFS in pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Patients with advanced abdominal cancers who are not candidates for tumor-removing surgery now have access to a treatment that may help control disease within the abdomen, reduce symptoms, preserve quality of life, and potentially extend survival.
The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.
Dabogratinib led to a high rate of responses FGFR3-altered low-grade intermediate-risk non–muscle-invasive bladder cancer.
Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.
A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sevabertinib for Advanced HER2 TKD–Mutated Nonsquamous NSCLC
2
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5